Another phase I clinical trial testing the safety and maximum tolerated dose of the STING agonist TAK-500, alone or with pembrolizumab, a monoclonal antibody targeting PD-1, is currently recruiting patients with locally advanced or metastatic solid tumors, however, MPNST is not one of the eligible tumor types (ClinicalTrials.gov ID, NCT05070247). Here, PDCD1 is linked to malignant peripheral nerve sheath tumor.